Shire PLC (LON:SHP)‘s stock had its “overweight” rating restated by investment analysts at JPMorgan Chase & Co. in a research note issued on Friday, April 21st.
SHP has been the subject of a number of other research reports. Deutsche Bank AG reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, January 3rd. Goldman Sachs Group Inc reaffirmed a “buy” rating and set a GBX 6,800 ($87.78) target price on shares of Shire PLC in a report on Wednesday, April 12th. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($71.00) price target on shares of Shire PLC in a research report on Thursday, December 22nd. BNP Paribas reissued an “outperform” rating and set a GBX 5,900 ($76.16) price target on shares of Shire PLC in a research report on Wednesday, March 22nd. Finally, Jefferies Group LLC reissued a “buy” rating and set a GBX 6,600 ($85.19) price target on shares of Shire PLC in a research report on Friday, February 17th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of GBX 6,108.38 ($78.85).
Shares of Shire PLC (LON:SHP) traded up 0.78% during midday trading on Friday, hitting GBX 4852.00. 3,402,129 shares of the stock traded hands. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The firm’s market capitalization is GBX 43.87 billion. The company’s 50-day moving average is GBX 4,628.66 and its 200 day moving average is GBX 4,654.33.
ILLEGAL ACTIVITY WARNING: “Shire PLC (SHP) Given “Overweight” Rating at JPMorgan Chase & Co.” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/05/20/shire-plc-shp-stock-rating-reaffirmed-by-jpmorgan-chase-co-updated-updated-updated.html.
In other news, insider William Burns bought 136 shares of the business’s stock in a transaction that occurred on Friday, March 31st. The shares were purchased at an average cost of GBX 4,742 ($61.21) per share, for a total transaction of £6,449.12 ($8,324.67).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.